Lv71
4180 积分 2024-01-24 加入
Sunvozertinib: the next candidate of TKI for NSCLC
1年前
已完结
EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)
1年前
已完结
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer
1年前
已完结
The global burden of lung cancer: current status and future trends
1年前
已完结
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
1年前
已完结
皖公网安备34019202002308
